Regional Yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 4, 2006, Pages 305-313

  Wong, Ching Yee Oliver ^a   Savin, Michael ^a   Sherpa, Kanchi M ^a   Qing, Feng ^a   Campbell, Janice ^a   Gates, Vanessa L ^b   Lewandowski, Robert J ^b   Cheng, Vincent ^a   Thie, Joseph ^c   Fink Bennett, Darlene ^a   Nagle, Conrad ^a   Salem, Riad ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Liver metastasis; Positron emission tomography; Y 90 microsphere

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MACROSALB TC 99M; MICROSPHERE; MICROSPHERE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER ANGIOGRAPHY; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG SHUNTING; MALE; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CITRATES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 33750157029     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.305     Document Type: Article

References (27)

1. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radial (Suppl 9)13:8259.
2. 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18-F]FDG-PET: A comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002;29(6):815.
3. 2 glasses for the in vivo delivery of beta radiation. J Biomed Mat Res 1993;27:1301.
4. 90Y-microspheres, J Nucl Med 2000;41:1673.
5. Ho S, Lau WY, Leung TWT, et al. Clinical evaluation of the partition model for estimating radiation doses from Yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293.
6. 18F FDG-PET. J Nucl Med 2004;45(11):1892.
7. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intra-arterial hepatic yttrium-90 radioembolization as evaluated by [18-F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005;16(8):1101.
8. Salem R, Lewandowski R, Oman B, et al. Use of yttrium-90 glass microspheres (Therasphere®) for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15(4):335.
9. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: Improved treatment with intra-arterial yttrium-90. Radiology 1988;169(2):311.
10. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust NZ J Surg 1992;62(2):105.
11. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90-yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001;5(3):294.
12. Fox RA, Klemp PF, Egan G, et al. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys 1991;21(2):463.
13. Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46(2):487.
14. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta-particles in water and other media. J Nucl Med 1971;NM/MIRD(Suppl 5):Pamphlet No. 7:7.
15. Snyder WS, Ford MR, Warner GG, et al. S absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975-1976.
16. Wong CYO, Thie J, Parling-Lynch KJ, et al. Glucose-normalized standard uptake value (SUV) from F-18 FDG-PET in classifying lymphomas. J Nucl Med 2005;46(10):1659.
17. Thie JA, Hubner KF, Smith GT. The diagnostic utility of the lognormal behavior of PET-standardized uptake values in tumors. J Nucl Med 2000;41(10):1664.
18. Patel N, Sacks D, Patel RI, et al. SIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol 2003;14(9 Pt. 2):S453.
19. Selzner M, Hany TF. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240(6):1027.
20. 18F FDG-PET on managing patients with colorectal cancer: The referring physician's perspective. J Nucl Med 2001;42:586.
21. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002;27(8):550.
22. Valk PE, Abella-Columna E, Hasemann MK, et al. Whole-body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503.
23. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4(8):613.
24. Koukourakis MI. Tumor angiogenesis and response to radiotherapy. Anticancer Res 2001;21(6B):4285.
25. 18F FDG-PET and PET/CT. AJR 2005;184:1096.
26. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 Trial of SIR-Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78.
27. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001;233(3):310.